Influenza A virus vaccine H5N1 - Adimmune Corporation

Drug Profile

Influenza A virus vaccine H5N1 - Adimmune Corporation

Alternative Names: AdimFlu-W; Adjuvanted H5N1 influenza virus vaccine - Adimmune; Pandemic influenza virus vaccine H5N1 - Adimmune

Latest Information Update: 14 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adimmune Corporation
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Influenza A virus H5N1 subtype

Most Recent Events

  • 14 Dec 2015 Clinical development is ongoing in Taiwan
  • 01 Jul 2012 Phase-I/II clinical trials in Influenza-A virus H5N1 subtype (prevention) in Taiwan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top